Skip Navigation

European Journal of Heart Failure 2005 7(5):809-814; doi:10.1016/j.ejheart.2004.10.011
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kupari, M.
Right arrow Articles by Parikka, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kupari, M.
Right arrow Articles by Parikka, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society of Cardiology

Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis

Markku Kupari*, Heikki Turto, Jyri Lommi, Markku Mäkijärvi and Hannu Parikka

Division of Cardiology, Department of Medicine, Helsinki University Central Hospital, 00029 HUS, Helsinki, Finland

* Corresponding author. Tel.: +358 9 47172441 fax: +358 9 47174574. markku.kupari{at}hus.fi


  Abstract

Background: Plasma B-type natriuretic peptide (BNP), as well as the N-terminal part of the prohormone (Nt-BNP), are frequently elevated in aortic valve stenosis (AS). Yet, their release from the heart into the circulation has never been directly studied in AS.

Aim: To assess the release of Nt-BNP in AS with focus on the identification of its main determinants.

Methods: We studied 49 adult patients undergoing preoperative cardiac catheterization for isolated AS. Blood was sampled from the aortic root and the coronary sinus for Nt-BNP determination by immunoassay.

Results: The mean (±S.E.) transcardiac Nt-BNP step-up averaged 79±53 pmol/l in 11 control patients free of structural heart disease, 75±32 pmol/l in 31 AS patients free of heart failure (HF), 236±62 pmol/l in 8 AS patients with diastolic HF (ejection fraction ≥50%, pulmonary wedge pressure >14 mm Hg) and 469±66 pmol/l in 7 AS patients with systolic HF (ejection fraction <50%, wedge pressure >14 mm Hg) (p<0.001). The transcardiac Nt-BNP gradient was independently associated with left ventricular (LV) end-diastolic pressure (β=0.47, p<0.001) and ejection fraction (β=–0.29, p<0.019) and with co-existent coronary artery disease (β=0.23, p=0.050).

Conclusion: LV diastolic and systolic dysfunction along with coronary artery disease are likely to be the key determinants of cardiac Nt-BNP release in AS. The transcardiac Nt-BNP gradient increases on average three-fold with the development of diastolic HF and six-fold in systolic HF.

Key Words: Natriuretic peptides • Aortic valve stenosis • Heart failure

Received June 8, 2004; Revised August 1, 2004; Accepted October 14, 2004


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
S. C. Palmer, T. G. Yandle, M. G. Nicholls, C. M. Frampton, and A. M. Richards
Regional clearance of amino-terminal pro-brain natriuretic peptide from human plasma
Eur J Heart Fail, September 1, 2009; 11(9): 832 - 839.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.